NextCure (NXTC) Other Non-Current Liabilities (2021 - 2026)
NextCure (NXTC) posted quarterly Other Non-Current Liabilities of $491000.0 for Q1 2026, down 21.94% year-over-year from $629000.0 in Q1 2025, and down 6.65% quarter-over-quarter from $526000.0 in Q4 2025.
NextCure (NXTC) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
NextCure's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $491000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 21.94% year-over-year to $491000.0; the TTM figure through Mar 2026 stood at $491000.0 (down 21.94% YoY), while the FY2025 annual figure was $526000.0, down 20.42% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $491000.0, down from $526000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $899000.0 in Q4 2022, with the low at $491000.0 in Q1 2026.
- The 5-year median for Other Non-Current Liabilities is $709000.0 (2024), against an average of $703642.9.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 62.42% in 2022, then decreased 12.68% in 2023.
- NextCure's Other Non-Current Liabilities stood at $899000.0 in 2022, then fell by 12.68% to $785000.0 in 2023, then retreated by 15.8% to $661000.0 in 2024, then fell by 20.42% to $526000.0 in 2025, then retreated by 6.65% to $491000.0 in 2026.
- Business Quant data shows NXTC's Other Non-Current Liabilities at $491000.0 in Q1 2026, $526000.0 in Q4 2025, and $561000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 455,000.00 |
| Mar 31, 2026 | 491,000.00 |
| Dec 31, 2025 | 526,000.00 |
| Sep 30, 2025 | 561,000.00 |
| Jun 30, 2025 | 596,000.00 |
| Mar 31, 2025 | 629,000.00 |
| Dec 31, 2024 | 661,000.00 |
| Sep 30, 2024 | 693,000.00 |
| Jun 30, 2024 | 725,000.00 |
| Mar 31, 2024 | 755,000.00 |
| Dec 31, 2023 | 785,000.00 |
| Sep 30, 2023 | 815,000.00 |
| Jun 30, 2023 | 843,000.00 |
| Mar 31, 2023 | 872,000.00 |
| Dec 31, 2022 | 899,000.00 |
| Dec 31, 2021 | 2.39 Mn |